Drugs / AEE788
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00118456 | Jul 2003 → Jan 2008 | cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00116376 | Jan 2004 → Nov 2005 | glioblastoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT00107237 | Oct 2003 → Jun 2006 | central nervous system neoplasm | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AEE788 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00118456 ↗ |
| Known as | GNF-PF-5343 | ChEMBL registry synonym — accepted as the source's own label CHEMBL587723 ↗ |
| Known as | NVP-AEE-788 | ChEMBL registry synonym — accepted as the source's own label CHEMBL587723 ↗ |
| Action | Inhibit | “AEE788 and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.” NCT00107237 ↗3“Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL587723 ↗ “Vascular endothelial growth factor receptor 1 inhibitor” CHEMBL587723 ↗ “Receptor protein-tyrosine kinase erbB-2 inhibitor” CHEMBL587723 ↗ |
| Modality | Small molecule | — CHEMBL587723 ↗ |
| Route | Oral | “Patients receive oral AEE788 once daily and oral everolimus once daily on days 1-28.” NCT00107237 ↗ |
| Target | EGFR | “IC50 of less than 100 nM against p-EGFR” NCT00118456 ↗ |
| Target | ERBB2 | “Receptor protein-tyrosine kinase erbB-2 inhibitor” CHEMBL587723 ↗ |
| Target | FLT1 | “Vascular endothelial growth factor receptor 1 inhibitor” CHEMBL587723 ↗ |
| Target | KDR | “Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL587723 ↗ |